Respiratory medication use in Australia 2003–2013: Treatment of asthma and COPD AIHW: Correll PK, Poulos LM, Ampon R, Reddel HK and Marks GB. Published.

Slides:

Advertisements

Similar presentations

Prepared by Margo Eyeson-Annan New South Wales Health Survey Program, Centre for Epidemiology and Research New South Wales Department of Health March 2006.

Advertisements

Chapter 5 Use of Health Services. Types of health service use for exacerbations of asthma.

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Meredith G. Hennon, MPH and the Supercourse team in Pittsburgh.

Chapter 3 Asthma control and quality of life. Dispensing of short-acting beta-agonists among concession card holders taking medications for asthma or.

Chapter 2 Prevalence, incidence and natural history.

Chapter 8 - Focus Chapter : Chronic obstructive pulmonary disease among people aged 55 years and over.

Asthma 2009: Overview of Asthma Prevalence & Mortality Karen Meyerson, MSN, RN, FNP-C, AE-C Asthma Network of West Michigan April 21, 2009.

1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.

Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

Trends in Spending on Selective Beta 2 Agonists in General Practice in England.

Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.

Bronchial Asthma  Definition  Patho-physiology  Diagnosis  Management.

Asthma in Australia 2003 Figures from: Australian Centre for Asthma Monitoring 2003 Asthma in Australia 2003 AIHW Asthma Series 1. AIHW Cat. No. ACM 1.

Assessing Control & Adjusting Therapy in Youths > 12 Years of Age & Adults *ACQ values of 0.76–1.4 are indeterminate regarding well-controlled asthma.

A-50 Table 7.1: U.S. Population Trends and Projections (1) by Age, 1980 – 2050 Source: U.S. Department of Commerce, Bureau of the Census. U.S. Interim.

Percentage of inpatients by board cause group , Thailand Sources: Individual patient information under the Universal Coverage Scheme, Civil Servant.

The (ab)use of symptom scores in asthma clinical trials: a systematic review Geoff Frampton & Jonathan Shepherd Southampton Health Technology Assessments.

Component 4 Medications.

Ali …. 65 years old C/O exercise intolerance for 2 years.

Trends in Spending on Selective Beta 2 Agonists in General Practice in England © Copyright NHSBSA 2009.

A-50 Table 7.1: U.S. Population Trends and Projections (1) by Age, 1980 – 2050 Source: U.S. Department of Commerce, Bureau of the Census. Projections.

Accessibility to Inhaled Cortico-steroids among Adults with Chronic Asthma: AN IMPACT OF THE UNIVERSAL HEALTH CARE COVERAGE POLICY Chulaporn Limwattananon,

Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:

Accessibility to Inhaled Cortico-steroids among Adults with Chronic Asthma: AN IMPACT OF THE UNIVERSAL HEALTH CARE COVERAGE POLICY Chulaporn Limwattananon,

History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.

A-52 Table 7.1: U.S. Population Trends and Projections by Age, 1980 – 2060 (1) Source: U.S. Department of Commerce, Bureau of the Census. Projections.

ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.

Diagnosing and Managing Asthma in Children LARRY S. POSNER M.D. Associate Clinical Professor of Pediatrics, UCSF Principal, North Bay Allergy and Asthma.

Wendy Pigg Practice support Pharmacist/Independent Prescriber

Overview of Changes to the NAEP Asthma Guidelines Breathe California’s Clinical Asthma Collaborative Susan M. Pollart, MD, MS University of Virginia Family.

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.

Diabetes: 0–44 years Ranked comorbidity combinations Source: ABS Australian Health Survey 2011–12 (National Health Survey component) For people aged 0–44,

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Use of Inhaled Corticosteroids and the Risk.

Linda Rogers and Joan Reibman Curr Opin Pulm Med. (2012) January Vol. 18 Stepping down asthma treatment: how and when Journal club R4. Yoo,

Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.

Dr Mazen Qusaibaty MD, DIS / Head Pulmonary and Internist Department Ibnalnafisse Hospital Ministry of Syrian health – Dr Mazen.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

Respiratory Health Asthma and COPD. Definition of asthma 2 Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation.

Asthma in Australia Hospitalisations and emergency department visits

Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: A population-based study

Research where it is most needed National Respiratory Strategy

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Patterns of asthma medications prescriptions among adult patients in the chest and accident and emergency units of a tertiary health care facility in Uganda.

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Antonio Anzueto, MD, Marc Miravitlles, MD CHEST

Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma Willem M.C. van Aalderen, MD, PhD, Jonathan Grigg,

The ABCs of Asthma Control

The Role of the Primary Care Physician in Helping Adolescent and Adult Patients Improve Asthma Control Barbara P. Yawn, MD, MSc Mayo Clinic Proceedings

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD

Volume 153, Issue 4, Pages (April 2018)

Volume 153, Issue 4, Pages (April 2018)

Asthma diagnosis and treatment: Filling in the information gaps

The Modern Management of Asthma: Getting it right Part 2

12 months before treatment 12 months after treatment

Global Initiative for Asthma (GINA) What’s new in GINA 2015?

Michael E. Wechsler, MD Mayo Clinic Proceedings

Roflumilast negli studi di Fase III: i dati di efficacia

Pinja Ilmarinen, PhD, Leena E

The efficacy and safety of omalizumab in pediatric allergic asthma

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Benefit–risk balance and its individual determinants with personalised chronic obstructive pulmonary disease (COPD) treatment choices. Benefit–risk balance.

Inhaled bronchodilators in maintenance treatment of chronic obstructive pulmonary disease; historical evolution along the lines of evidence. Inhaled bronchodilators.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to previous chronic obstructive pulmonary.

Comparison of total β2-agonist coverage for patients prescribed a) an increased dose of extrafine inhaled corticosteroids (ICS) versus ICS+long-acting.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Choosing inhaler therapy for patients with stable COPD based on the Global Initiative for Chronic Obstructive Lung Disease grouping. Choosing inhaler therapy.

Presentation transcript:

Respiratory medication use in Australia 2003–2013: Treatment of asthma and COPD AIHW: Correll PK, Poulos LM, Ampon R, Reddel HK and Marks GB. Published 5 May 2015 Available at

Data sources

Note: Self-reported frequency of SABA use in the last 4 weeks, NSW, 2009, 2010 and 2012 (combined data), people aged 2 and over Use of SABA for Asthma (NSW Health Survey) Proportion of people with current asthma in each frequency category Source: NSW Health Survey Program, NSW Ministry of Health 2009, 2010, 2012.

Trends in frequency of dispensing ICS-containing medications Proportion of concession card holders dispensed any ICS (as % of all Australian concession card holders) Proportions of concession card holders dispensed any ICS Source: Pharmaceutical Benefits Scheme Database, Department of Health.

Variations in ICS dispensing patterns by age (2013) Proportion of Australian populationProportions of Australian population dispensed any ICS Source: Pharmaceutical Benefits Scheme Database, Department of Health.

Variations in ICS dispensing patterns in children by remoteness Proportion (%) of child populationProportions (%) of child population dispensed any ICS Source: Pharmaceutical Benefits Scheme Database, Department of Health. Note: Children aged 0–14 years, 2013

Variations in ICS dispensing patterns in adults by remoteness Note: Adults aged 15 and over, 2013 Proportion (%) of adult populationProportions (%) of adult population dispensed any ICS Source: Pharmaceutical Benefits Scheme Database, Department of Health.

Potency of ICS dispensed in 2013 Source: Pharmaceutical Benefits Scheme Database, Department of Health. ICS potency category and age group (years) Proportion (%) of Australian children Proportion (%) of Australian adults 2–3 4–6 7– and 1+ other resp meds 1 and no other resp meds No. ICS scripts dispensed per year

Potency of ICS Source: Pharmaceutical Benefits Scheme Database, Department of Health. Proportion of people dispensed any ICS in 2013

Note: Concession card holders aged 15 and over Trends in potency of ICS dispensed Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Proportion of concession card holders dispensed any ICS (as % of all Australian concession card holders) Proportions of concession card holders dispensed any ICS

Potency of ICS (Seretide) Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Note: Concession card holders aged 15 and over Proportion of concession card holders dispensed Seretide (as % of all Australian concession card holders) Proportions of concession card holders dispensed Seretide

Potency of ICS (Symbicort) Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Note: Concession card holders aged 15 and over Proportion of concession card holders dispensed Symbicort (as % of all Australian concession card holders) Proportions of concession card holders dispensed Symbicort

Combined ICS and long acting beta 2 -agonist formulations Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Proportion (%) of Australian population dispensed ICS/LABA in –3 4–6 7– and 1+ other resp meds 1 and no other resp meds No. ICS/LABA scripts dispensed in 2013

Self-reported use of ICS for asthma (NSW Health Survey) Note: Self-reported frequency of ICS use in the last 4 weeks, NSW, 2009, 2010 and 2012 (combined data), Children aged 2–14, adults aged 15+ Source: NSW Health Survey Program, NSW Ministry of Health 2009, 2010, Proportion of people with current asthma in each frequency category

Oral corticosteroids Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Proportion (%) of people dispensed OCS (and any respiratory medication) in 2013

Long-acting bronchodilators (LABA and LAMA) dispensed without ICS Sources: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Proportion (%) of the population dispensed LABA, LAMA or both LABA and LAMA, without any ICS within the same year (2013)

Anti-immunoglobulin E therapy (omalizumab) Source: Pharmaceutical Benefits Scheme Database, Department of Health. No. omalizumab scripts dispensed per month Cumulative frequency

Anti-immunoglobulin E therapy (omalizumab) Source: Pharmaceutical Benefits Scheme Database, Department of Health. No. new patients dispensed omalizumab per month Cumulative frequency

Anti-immunoglobulin E therapy (omalizumab) Source: Pharmaceutical Benefits Scheme Database, Department of Health. Proportion of people still taking omalizumab

Leukotriene receptor antagonists Source: Pharmaceutical Benefits Scheme Database, Department of Health. Proportion (%) of Australian childrenProportions of children dispensed LTRA 2–3 4–6 7– and 1+ other resp meds 1 and no other resp meds No. LTRA scripts dispensed in 2013

Leukotriene receptor antagonists Source: Pharmaceutical Benefits Scheme Database, Department of Health; Estimated Resident Population, Australian Bureau of Statistics. Proportion (%) of Australian childrenProportions of children dispensed LTRA 2–3 4–6 7– and 1+ other resp meds 1 and no other resp meds No. LTRA scripts dispensed in 2013

People dispensed preventer inhalers in 2013 Probably do not need preventers* Infrequent* use of preventers Regular* use of preventers * medication history suggests unlikely to have chronic respiratory disease * medication history suggests dispensing consistent with regular use * medication history suggests dispensing inconsistent with infrequent use